Page 15 - Solid Tumors News Today

Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting...

This marks the first and only time that an individualized T cell therapy has been approved by the FDA for a solid tumor cancer.

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune...

The Food and Drug Administration will review Augtyro for potential approval in children and adults with advanced solid cancers that harbor NTRK gene fusions.

PRINCETON, N.J.--(BUSINESS WIRE)--Feb 14, 2024--

Discover the potential of personalized drug testing for cancer treatment, but with caveats. Find out how this

The Janssen pharmaceutical companies of Johnson & Johnson announce that they have applied to the European Medicines Agency for an extension of the indication for Rybrevant . The idea is to obtain...

Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.

Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.

The first set of guidelines for treating solid tumors in children, published by the National Comprehensive Cancer Network.